PI-103

製品コードS1038

PI-103化学構造

分子量(MW):348.36

PI-103は一種の多ターゲットPI3K阻害剤で、無細胞試験でp110α/β/δ/γに作用する時のIC50値は2 nM/3 nM/3 nM/15 nMです。PI-103はmTOR/DNA-PKに作用する効果が弱くて、このIC50値が30 nM/23 nMになります。

サイズ 価格(税別)  
JPY 22244.00
JPY 24402.00
JPY 44820.00
JPY 61420.00

カスタマーフィードバック(5)

  • (D) IGROV parental, shControl (two independent clones) and ShPKCiota (two independent clones) were treated with 5 μM GDC-0941 and 1.5 μM PI-103 for 24 hours and subjected to western blot analysis with the indicated antibodies. Each experiment was performed in triplicate.

    Oncogene, 2016, 35(19):2428-40. PI-103 purchased from Selleck.

    (A) MCF7 cells pre-treated with 100 nM siRNA for 72 h were re-seeded with normal growth media and grown overnight, then further transfected by 100nM of fresh siRNA. Twenty-(A) four hours after transfection, the cells were further treated with PI-103 for 24 h and the cell lysates were immunoblotted with the indicated antibodies. (B) Breast cancer cells carrying BRCA1 mutations were treated with 1 mM of PI-103 for 24h (left) or increasing amounts of PI-103 for 24 h (right). Cell lysates were analyzed by Western blotting with the indicated antibodies.

    Mol Carcinog 2012 52, 667-75 . PI-103 purchased from Selleck.

  • Knockdown of BRCA1 sensitizes cells to PI3K/AKT pathway inhibitors. MCF7 cells transfected with either BRCA1-siRNA or control-siRNA were treated with increasing amounts of inhibitors targeting the PI3K/AKT pathway for 48 h in triplicate. Viable cells were measured by MTT assay.

    Mol Carcinog 2012 ahead of print. PI-103 purchased from Selleck.

    Breast cancer cells were pretreated with 100ng/ml EGF for 15 min and then treated with the indicated concentrations of PI-103 for 24 hours.

     

     

    Dr. Zhang of Tianjin Medical University. PI-103 purchased from Selleck.

  • We treated all of drugs in T47D which has a PI3KCA H1044R mutation with the concentration shown below for 1 hour and performed western blot analysis using antibodies to phospho-AKT(SERINE 472), and total AKT.

     

     

    Saraswati Sukumar of Johns Hopkins University School of Medicine PI-103 purchased from Selleck.

製品安全説明書

PI3K阻害剤の選択性比較

生物活性

製品説明 PI-103は一種の多ターゲットPI3K阻害剤で、無細胞試験でp110α/β/δ/γに作用する時のIC50値は2 nM/3 nM/3 nM/15 nMです。PI-103はmTOR/DNA-PKに作用する効果が弱くて、このIC50値が30 nM/23 nMになります。
特性 The first potent, synthetic mTOR inhibitor.
ターゲット
p110α [3]
(Cell-free assay)
p110β [3]
(Cell-free assay)
p110δ [3]
(Cell-free assay)
p110γ [3]
(Cell-free assay)
DNA-PK [3]
(Cell-free assay)
2 nM 3 nM 3 nM 15 nM 23 nM
体外試験

PI-103 potently inhibits both the rapamycin-sensitive (mTORC1) and rapamycin-insensitive (mTORC2) complexes of the protein kinase mTOR. [1] PI-103 inhibits constitutive and growth factor-induced PI3K/Akt, as well as mTORC1 activation. [2] In blast cells, PI-103 inhibits leukemic proliferation, the clonogenicity of leukemic progenitors and induces mitochondrial apoptosis, especially in the compartment containing leukemic stem cells. PI-103 inhibits p110α >200-fold more potently than p110β. PI-103 also potently blocks production of PI(3,4)P2 and PIP3 in adipocytes and PIP3 in myotubes. [2] PI-103 inhibits phosphorylation of Akt with an IC95 100-fold lower than that for LY294002. Strikingly, PI-103 completely protects animals from insulin-stimulated decline in blood glucose. PI-103 has additive proapoptotic effects with etoposide in blast cells and in immature leukemic cells. [2]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SK-N-BE NVfBNXdPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGq2dHIxNThizszN Mn73NlQwPDhxN{KgbC=> MVLpcoR2[2W|IITpcYUuKGGwZDDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCrbnjpZol1cW:wIH;uJG5DKGOnbHyg[5Jwf3Sq Mne1NlYzOjR4OEG=
SH-SY5Y NEHrWopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;INE05KM7:TR?= NYTOWlJjOjRxNEivO|IhcA>? MUfpcoR2[2W|IITpcYUuKGGwZDDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCrbnjpZol1cW:wIH;uJG5DKGOnbHyg[5Jwf3Sq NWjX[phnOjZ{MkS2PFE>
SH-SY5Y  NXzlVVFjSXCxcITvd4l{KEG|c3H5 NX;Wc|d4OSEQvF2= NUHwb204OC53LUK0JIg> MnLhd4Vve2m2aYrld{Bv\XW{b3LsZZN1d22jIHPlcIx{KHSxIHTvfI9zfWKrY3nuMYlv\HWlZXSgZZBweHSxc3nz MWiyOlIzPDZ6MR?=
G 35 SC NV3HOYRVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGfENoIxNjB3LUKwJO69VQ>? NFr1SYEzPC95MjDo MmPTSG1UVw>? M{DLNYlvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh[W6mIITpcYUh\GWyZX7k[Y51dHl? NYfvfo5MOjZzMkGyOVE>
G 38 SC MoWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3GzR|AvODVvMkCg{txO MXmyOE84OiCq MojCSG1UVw>? MUPpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIFv\CC2aX3lJIRmeGWwZHXueIx6 MojrNlYyOjF{NUG=
G 40 SC M1raZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NETzS24xNjB3LUKwJO69VQ>? MVyyOE84OiCq MnLpSG1UVw>? M1jEOolvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh[W6mIITpcYUh\GWyZX7k[Y51dHl? Mlf2NlYyOjF{NUG=
G 35 DC NVPlSlFKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUfMbGVwOC5yNT2yNEDPxE1? MY[yOE84OiCq M{D6OWROW09? Mn7rbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBidmRidHnt[UBl\XCnbnTlcpRtgQ>? NE[5bG0zPjF{MUK1NS=>
G 38 DC MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUOwMlA2NTJyIN88US=> NYDrVXlNOjRxN{KgbC=> NHy1SnpFVVOR MVLpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIFv\CC2aX3lJIRmeGWwZHXueIx6 MlSzNlYyOjF{NUG=
G 40 DC NX3tVGI4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M16zT|AvODVvMkCg{txO NITWOYUzPC95MjDo NGTScllFVVOR MYrpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIFv\CC2aX3lJIRmeGWwZHXueIx6 MYOyOlEzOTJ3MR?=
RD M1P2TGFxd3C2b4Ppd{BCe3OjeR?= NYSw[mRlOS9zLkWvNkDPxE1? Mo\KO|IhcA>? MlvnbY5lfWOnczDhdI9xfG:|aYOgZ49u[mmwZXSge4l1cCCJQV7UOlE> NGHGNXgzPTd2OUO3PC=>
TE381.T MoPyRZBweHSxc3nzJGF{e2G7 NHLxeVIyNzFwNT:yJO69VQ>? MnHqO|IhcA>? NIDTfGZqdmS3Y3XzJIFxd3C2b4Ppd{Bkd22kaX7l[EB4cXSqIFfBUnQ3OQ>? NUTNeohLOjV5NEmzO|g>
RMS13 M1LWcGFxd3C2b4Ppd{BCe3OjeR?= NX3PXlZMOS9zLkWvNkDPxE1? MlP2O|IhcA>? MX\pcoR2[2W|IHHwc5B1d3OrczDjc41jcW6nZDD3bZRpKEeDTmS2NS=> M{jUO|I2PzR7M{e4
RH30  M{m1U2Fxd3C2b4Ppd{BCe3OjeR?= NF;Zc5YyNzFwNT:yJO69VQ>? MlHqO|IhcA>? MkLabY5lfWOnczDhdI9xfG:|aYOgZ49u[mmwZXSge4l1cCCJQV7UOlE> M{H6OVI2PzR7M{e4
VJ NVGwe2RPSXCxcITvd4l{KEG|c3H5 M4PxO|EwOS53L{Kg{txO M3Ww[FczKGh? M1OwO4lv\HWlZYOgZZBweHSxc3nzJINwdWKrbnXkJJdqfGhiR1HOWFYy MW[yOVc1QTN5OB?=
HS578T MY\D[YxtKF[rYXLpcIl1gSCDc4PhfS=> NULwUXhlOC1|IN88US=> MWe3NkBp MXLpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6 MnrZNlU4OjF2MUm=
BT549 NUnmUWRGS2WubDDWbYFjcWyrdImgRZN{[Xl? NIjRc2gxNTNizszN NVfjO5BpPzJiaB?= MnPKbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>? NE\RV4ozPTd{MUSxPS=>
MDA-MB-231 NWjZcHozS2WubDDWbYFjcWyrdImgRZN{[Xl? Ml\kNE0{KM7:TR?= MXG3NkBp MWPpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6 NH7WRXAzPTd{MUSxPS=>
MDA-MB-468 MkT3R4VtdCCYaXHibYxqfHliQYPzZZk> NH22dYsxNTNizszN MnrKO|IhcA>? NXjLZ|EycW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?= NGnNdmozPTd{MUSxPS=>
MDA-MB-436 MnfiR4VtdCCYaXHibYxqfHliQYPzZZk> MlLYNE0{KM7:TR?= NE\tfpU4OiCq NVTO[VF[cW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?= NY\scW9{OjV5MkG0NVk>
SUM149PT Mm\vR4VtdCCYaXHibYxqfHliQYPzZZk> M{ixdFAuOyEQvF2= MoXxO|IhcA>? M3LOUIlvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl? NIPHdW4zPTd{MUSxPS=>
MDA-MB-468 NIDm[HpHfW6ldHnvckBCe3OjeR?= MWKwMlAyNTFyIN88US=> M2n2U|I1KGh? NInYW2pld3ewcnXneYxifGW|IITo[UBt\X[nbIOgc4Yh|rJvVILDVFEtKGNvTYnjJIFv\CCleXPsbY4hTSCycn;0[Ylve8Li MUOyOVczOTRzOR?=
MDA-MB-231 NFLkTpZHfW6ldHnvckBCe3OjeR?= M4LIVlAvODFvMUCg{txO MX6yOEBp M2jzS4Rwf26{ZXf1cIF1\XNidHjlJIxmfmWuczDv[kDPui2WclPQNUwh[y2PeXOgZY5lKGO7Y3zpckBGKHC{b4TlbY5{yqB? NFzHRpczPTd{MUSxPS=>
HS578T NGPmVpBHfW6ldHnvckBCe3OjeR?= M3fIeVAvODFvMUCg{txO MVeyOEBp MWfkc5dvemWpdXzheIV{KHSqZTDs[ZZmdHNib3[g{tIuXHKFUEGsJIMuVXmlIHHu[EBkgWOuaX6gSUBxem:2ZXnud:Kh M1LyV|I2PzJzNEG5
SW872 MYLGeY5kfGmxbjDBd5NigQ>? NFjnUWoxNjBzLUCuOUDPxE1? NWPiVFJEOjRiaB?= MWfy[YR2[2W|IFHLWEBxcG:|cHjvdplt[XSrb36gLJBCU1RrIHHu[EA1TUKSMTDwbI9{eGixconsZZRqd25iKIC0SWJROSliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XMEoB?= NUH5TZZqOjR4OUW2N|I>
SW982 MXvGeY5kfGmxbjDBd5NigQ>? MX:wMlAyNTBwNTFOwG0> NH7LV4ozPCCq M2HMPZJm\HWlZYOgRWtVKHCqb4PwbI9zgWyjdHnvckApeEGNVDmgZY5lKDSHQmCxJJBpd3OyaH;yfYxifGmxbjCodFRGSlBzKTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nctMg M3XlNVI1Pjl3NkOy
SW872 MkDyRZBweHSxc3nzJGF{e2G7 MXWwMlAyNTBwNTFOwG0> M4PQNlQ5KGh? NVLKW4VqcW6mdXPld{BieG:ydH;zbZMh\G:|ZTDk[ZBmdmSnboTsfS=> Mly4NlQ3QTV4M{K=
SW982 M{XBU2Fxd3C2b4Ppd{BCe3OjeR?= NGHtd5oxNjBzLUCuOUDPxE1? NF\ISWk1QCCq NXTwVVJpcW6mdXPld{BieG:ydH;zbZMh\G:|ZTDk[ZBmdmSnboTsfS=> NIr0b3czPDZ7NU[zNi=>
AGS HG NHLYZZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmP4TWM2OD1yLk[4JOKyKDBwMEOxJO69VQ>? MlnZNlQ2QTd2N{i=
AGS LG NXXXO2FCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;BcGlEPTB;MD6wOUDDuSByLkCwNUDPxE1? MmL6NlQ2QTd2N{i=
HGC27 HG MlriS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmDxTWM2OD1yLkO4JOKyKDBwMEKyJO69VQ>? NUHhNJhnOjR3OUe0O|g>
HGC27 LG NVKyTFk2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTBwMEKgxtEhOC5yMESg{txO M3qzOVI1PTl5NEe4
MKN45 HG M2TLdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\lTWM2OD1zLkCxJOKyKDBwMEWxJO69VQ>? MYWyOFU6PzR5OB?=
MKN45 LG MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGjBfFRKSzVyPUCuPFchyrFiMD6wN|Ah|ryP MU[yOFU6PzR5OB?=
NUGC4 HG NEPYW2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXXLOpc6UUN3ME2xOE4xKMLzIEOuPVE{KM7:TR?= NGOwcFIzPDV7N{S3PC=>
NUGC4 LG M4LlRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkjZTWM2OD1zND6wJOKyKDVwM{KxJO69VQ>? NIrtVoczPDV7N{S3PC=>
A549 NVjlXHp6TnWwY4Tpc44hSXO|YYm= Mnq4NE4zPS9yLkWvNUDPxE1? NUjpcoRuOjRiaB?= MnXBbY5pcWKrdIOgRYt1KHCqb4PwbI9zgWyjdHnvckB{dGmpaITsfS=> M1jHfFI1OzVzNEK1
H460 MWTGeY5kfGmxbjDBd5NigQ>? NGfDXHMxNjJ3L{CuOU8yKM7:TR?= Ml63NlQhcA>? NEfzfpZqdmirYnn0d{BCc3RicHjvd5Bpd3K7bHH0bY9vKHOuaXfoeIx6 MVKyOFM2OTR{NR?=
H661 MXXGeY5kfGmxbjDBd5NigQ>? NGHKbnAxNjJ3L{CuOU8yKM7:TR?= MVKyOEBp Ml75bY5pcWKrdIOgRYt1KHCqb4PwbI9zgWyjdHnvckB{cWewaX\pZ4FvfGy7 MoPiNlQ{PTF2MkW=
SAS MVLGeY5kfGmxbjDBd5NigQ>? M1TONFAvOjVxMD61M|Eh|ryP MnvTNlQhcA>? NG\0TYVqdmirYnn0d{BCc3RicHjvd5Bpd3K7bHH0bY9vKHOrZ37p[olk[W62bIm= MknYNlQ{PTF2MkW=
UT5 Mn;ISpVv[3Srb36gRZN{[Xl? NW[w[5ZlOC5{NT:wMlUwOSEQvF2= MXGyOEBp NYni[INLcW6qaXLpeJMhSWu2IIDoc5NxcG:{eXzheIlwdiC|aXfubYZq[2GwdHz5 MYmyOFM2OTR{NR?=
FaDu NFjuXmFHfW6ldHnvckBCe3OjeR?= NEjZS4QxNjJ3L{CuOU8yKM7:TR?= NILK[YYzPCCq MY\pcohq[mm2czDBb5QheGixc4Doc5J6dGG2aX;uJJNq\26rZnnjZY51dHl? MoT4NlQ{PTF2MkW=
RD MmXERZBweHSxc3nzJGF{e2G7 MVyxM|EvPS9{IN88US=> M2PPOlczKGh? NI\JbYdFVVOR Ml7ObY5lfWOnczDjZZNx[XOnLXTldIVv\GWwdDDhdI9xfG:|aYOgZ49u[mmwZXSge4l1cCCXT{GyOi=> M2W4SFI{Pjh2OUK1
TE671 MXnBdI9xfG:|aYOgRZN{[Xl? MU[xM|EvPS9{IN88US=> NW\wWWRxPzJiaB?= MXfEUXNQ MVLpcoR2[2W|IHPhd5Bie2VvZHXw[Y5l\W62IHHwc5B1d3OrczDjc41jcW6nZDD3bZRpKFWRMUK2 NGLWdmozOzZ6NEmyOS=>
RH30  NWPO[VI1SXCxcITvd4l{KEG|c3H5 Ml3kNU8yNjVxMjFOwG0> M4HDVlczKGh? MXTEUXNQ M{\GOYlv\HWlZYOgZ4F{eGG|ZT3k[ZBmdmSnboSgZZBweHSxc3nzJINwdWKrbnXkJJdqfGhiVV:xNlY> M4DQSVI{Pjh2OUK1
RMS13 MmLCRZBweHSxc3nzJGF{e2G7 MlrDNU8yNjVxMjFOwG0> MVO3NkBp MlPpSG1UVw>? NYL0[lNRcW6mdXPld{Bk[XOyYYPlMYRmeGWwZHXueEBieG:ydH;zbZMh[2:vYnnu[YQhf2m2aDDVU|EzPg>? MlLZNlM3QDR7MkW=
SUM149PT MXXD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MmDoNE4{KM7:TR?= NVHFc3pVPzJiaB?= M3[zPYVvcGGwY3XzJIN6fG:2b4jpZ{Bm\m[nY4TzJI9nKFCLM1uvRWtVKHCjdHj3ZZkhcW6qaXLpeI9zew>? NGWzS3IzOzZyMUC3OC=>
MDA-MB-468 M1zwW2NmdGxiVnnhZoltcXS7IFHzd4F6 NUPa[mhMOC5|IN88US=> MYm3NkBp Ml\l[Y5p[W6lZYOgZ5l1d3SxeHnjJIVn\mWldIOgc4YhWEl|Sz;BT3QheGG2aIfhfUBqdmirYnn0c5J{ MVOyN|YxOTB5NB?=
MDA-MB-231 NVfHZmVIS2WubDDWbYFjcWyrdImgRZN{[Xl? MmfQNE4{KM7:TR?= M3Tve|czKGh? MmTv[Y5p[W6lZYOgZ5l1d3SxeHnjJIVn\mWldIOgc4YhWEl|Sz;BT3QheGG2aIfhfUBqdmirYnn0c5J{ MW[yN|YxOTB5NB?=
SY5Y MX\GeY5kfGmxbjDBd5NigQ>? M3ewcVEvPS9{LkWvOUDPxE1? MoDwNlQhcA>? MoO4bY5lfWOnczDHNeKh[2WubD3jfYNt\SCjcoLld5Qh[W6mIHHwc5B1d3Orcx?= M4Hoc|I{Ozd6M{Sx
SKNBE(2c) MV7GeY5kfGmxbjDBd5NigQ>? MVixMlUwOi53L{Wg{txO NVHnXYJ4OjRiaB?= NGC1fIpqdmS3Y3XzJGcyyqClZXzsMYN6[2ynIHHydoV{fCCjbnSgZZBweHSxc3nz NVvFfpFjOjN|N{izOFE>
RD MmLERZBweHSxc3nzJGF{e2G7 MWOzJOK2VQ>? NH;iXoUyOiCq NWH0W4xmTE2VTx?= MXnz[Y5{cXSrenXzJHJFKGOnbHzzJJRwKESRWD3pcoR2[2WmIHHwc5B1d3Orcx?= MkXPNlM{ODB6MEm=
TP5014 NUHHXGJPSXCxcITvd4l{KEG|c3H5 M2\SVlMhyrWP NW[xZ3ZXOTJiaB?= M{i0OGROW09? NVewOGhUe2Wwc3n0bZpmeyCURDDj[YxteyC2bzDEU3gucW6mdXPl[EBieG:ydH;zbZM> M1XZZ|I{OzByOEC5
HT1080 NUfWUId2SXCxcITvd4l{KEG|c3H5 NFHWdlE{KML3TR?= MofCNVIhcA>? MkXuSG1UVw>? Ml7nd4Vve2m2aYrld{BTTCClZXzsd{B1dyCGT2itbY5lfWOnZDDhdI9xfG:|aYO= NUHpRWtwOjN|MEC4NFk>
A549 MYXGeY5kfGmxbjDBd5NigQ>? MlThNE0{NjNizszN M1flR|czKGh? NFPZSm9qdmS3Y3XzJINwdXCuZYTlJIRwf26{ZXf1cIF1cW:wIH;mJJBCU1R? MlnCNlMzPTl3OUG=
HCC827 NVvhW2JPTnWwY4Tpc44hSXO|YYm= NXux[mttOC1|LkOg{txO M2XDU|czKGh? M3nSTolv\HWlZYOgZ49ueGyndHWg[I94dnKnZ4XsZZRqd25ib3[gdGFMXA>? M2XPZVI{OjV7NUmx
H3122 M4jH[mZ2dmO2aX;uJGF{e2G7 MWewMVMvOyEQvF2= NUi1V5ZuPzJiaB?= M{LwUYlv\HWlZYOgZ49ueGyndHWg[I94dnKnZ4XsZZRqd25ib3[gdGFMXA>? NX7icW5rOjN{NUm1PVE>
TALL-1 NHPEcYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUTqPXV4OeLCid88US=> M2\0cFch\A>? MVrk[YNz\WG|ZYOgeIhmKGOnbHygcpVu[mW{IIPp[45q\mmlYX70cJk> MUSyN|A{QDJ5Mx?=
HPB-ALL MnjwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\P[|HjiIoQvF2= NHzKdYs4KGR? MlXn[IVkemWjc3XzJJRp\SClZXzsJI52dWKncjDzbYdvcW[rY3HueIx6 NHHQPWUzOzB|OEK3Ny=>
DND41 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUfQSpJMOeLCid88US=> NHXBcGg4KGR? NXLlVpVu\GWlcnXhd4V{KHSqZTDj[YxtKG63bXLldkB{cWewaX\pZ4FvfGy7 M3r2fFI{ODN6Mkez
SUP-T1 MkPMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXNfFYy6oDLzszN NXL0SoJMPyCm M3nUU4Rm[3KnYYPld{B1cGViY3XscEBvfW2kZYKgd4lodmmoaXPhcpRtgQ>? NIT1PWczOzB|OEK3Ny=>
PEER MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXyx5qCK|ryP NUGzbVNJPyCm NGrMUIdl\WO{ZXHz[ZMhfGinIHPlcIwhdnWvYnXyJJNq\26rZnnjZY51dHl? NEXoRokzOzB|OEK3Ny=>
ALL-SIL MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHv6N2Ey6oDLzszN Mn[3O{Bl MVXk[YNz\WG|ZYOgeIhmKGOnbHygcpVu[mW{IIPp[45q\mmlYX70cJk> NIfRUnozOzB|OEK3Ny=>
KE37 NYTPTJM2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TzSFHjiIoQvF2= MlyzO{Bl NUHweYd4\GWlcnXhd4V{KHSqZTDj[YxtKG63bXLldkB{cWewaX\pZ4FvfGy7 NYS2NIpxOjNyM{iyO|M>
Karpas-45 NEDNRplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVKx5qCK|ryP M4Huclch\A>? M3LsWYRm[3KnYYPld{B1cGViY3XscEBvfW2kZYKgd4lodmmoaXPhcpRtgQ>? MkTENlMxOzh{N{O=
RPMI-8402 MlG0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU\kb483OeLCid88US=> NX;UVINHPyCm NFHOfIll\WO{ZXHz[ZMhfGinIHPlcIwhdnWvYnXyJJNq\26rZnnjZY51dHl? NGW2[ZYzOzB|OEK3Ny=>
Jurkat NVPqUnJiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\RNIM6OeLCid88US=> MWO3JIQ> M4PDNoRm[3KnYYPld{B1cGViY3XscEBvfW2kZYKgd4lodmmoaXPhcpRtgQ>? Mln1NlMxOzh{N{O=
MOLT-4 M1vNS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2j6TFHjiIoQvF2= NWTHRYJFPyCm MmDR[IVkemWjc3XzJJRp\SClZXzsJI52dWKncjDzbYdvcW[rY3HueIx6 NWW5bYozOjNyM{iyO|M>
PF-382 NWjuXGRNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF3HcYcy6oDLzszN NVTJXlBlPyCm MV3k[YNz\WG|ZYOgeIhmKGOnbHygcpVu[mW{IIPp[45q\mmlYX70cJk> M2W4clI{ODN6Mkez
CCRF-CEM MlixS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH3GbHIy6oDLzszN NEPC[2Q4KGR? M4\iNYRm[3KnYYPld{B1cGViY3XscEBvfW2kZYKgd4lodmmoaXPhcpRtgQ>? NEPWSVAzOzB|OEK3Ny=>
LOUCY NF72OoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFm5V2wy6oDLzszN NX\QenRsPyCm MV\k[YNz\WG|ZYOgeIhmKGOnbHygcpVu[mW{IIPp[45q\mmlYX70cJk> M4LhOVI{ODN6Mkez
MOLT-16 MlLiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF6wTlEy6oDLzszN M3n3e|ch\A>? M1Lxc4Rm[3KnYYPld{B1cGViY3XscEBvfW2kZYKgd4lodmmoaXPhcpRtgQ>? NVm2O3BHOjNyM{iyO|M>
MM1S M1TXdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVuwMVIh|ryP NHLYW2MzPCCq NEDV[YdKSzVyPUCuOUDPxE1? NHTHbZgzOjh{OUKzOC=>
NCI-H929 NHjOU5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\HdpExNTJizszN MXqyOEBp NFHiZXJKSzVyPUCuNlUh|ryP M123S|IzQDJ7MkO0
KMS12-BM  MlXxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4XhR|AuOiEQvF2= Mm\sNlQhcA>? NGLqW5ZKSzVy78{eNkDPxE1? NEHyfm4zOjh{OUKzOC=>
MDA-MB-436 MXXGeY5kfGmxbjDBd5NigQ>? NHT3d2syKM7:TR?= M4fFXFI1KGh? NWHNcohOemWmdXPld{B1cGVicHjvd5Bpd3K7bHH0bY9vKG:oIFHLWC=> MYOyNlQ5QDV7MB?=
SUM149PT MVjGeY5kfGmxbjDBd5NigQ>? MlS5NUDPxE1? NFK3RXYzPCCq NHK2dZhz\WS3Y3XzJJRp\SCyaH;zdIhwenmuYYTpc44hd2ZiQVvU NHnSW2IzOjR6OEW5NC=>
SUM1315MO2 NUPke3NPTnWwY4Tpc44hSXO|YYm= NUnIVpBNOSEQvF2= MXOyOEBp MmnmdoVlfWOnczD0bIUheGixc4Doc5J6dGG2aX;uJI9nKEGNVB?= NYnHXoR4OjJ2OEi1PVA>
HCC1937 NXSwTll5TnWwY4Tpc44hSXO|YYm= Ml[2NUDPxE1? MYeyOEBp M3\IOZJm\HWlZYOgeIhmKHCqb4PwbI9zgWyjdHnvckBw\iCDS2S= M4naZ|IzPDh6NUmw
HCC827 M4izUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXmwMVMh|ryP MlzYO|IhcA>? NVnIc2RQUUN3ME2wMlMh|ryP NE\YWmszOTJ{MES3OC=>
PC-9  NUm5bWozT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFftWWwxNTNizszN NGOxVHk4OiCq NEP3e|hKSzVyPUCuPEDPxE1? NH\TSXAzOTJ{MES3OC=>
LN229 NH65SZRHfW6ldHnvckBCe3OjeR?= MXuxJO69VQ>? MoLiOFghcA>? NHHzRoFqdmS3Y3XzJIF2fG:yaHHnc5NwdWViZn;ycYF1cW:w NFzud|QzOTB4Mkm5Ny=>
U87 MWPGeY5kfGmxbjDBd5NigQ>? NYHwfVdWOSEQvF2= MX:0PEBp Ml\ibY5lfWOnczDheZRweGijZ3;zc41mKG[xcn3heIlwdg>? MmHrNlExPjJ7OUO=
U373 NXHtfHlHTnWwY4Tpc44hSXO|YYm= NHLjd4wyKM7:TR?= NWrMWmo3PDhiaB?= NF;SbWZqdmS3Y3XzJIF2fG:yaHHnc5NwdWViZn;ycYF1cW:w NEnNNlMzOTB4Mkm5Ny=>
SF767 NVLJe4ZPTnWwY4Tpc44hSXO|YYm= M1\vfVEh|ryP NH\tS|A1QCCq MW\pcoR2[2W|IHH1eI9xcGGpb4PvcYUh\m:{bXH0bY9v M2e1SFIyODZ{OUmz
Mel-Juso NXKyUpNXS2WubDDWbYFjcWyrdImgRZN{[Xl? NVXBflViOC5yMfMAl|Ex6oDLzszN M{PkVlczKGh? MkC5bY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>? NGq5OHkzOTB2OEe4OS=>
518A2  MlriR4VtdCCYaXHibYxqfHliQYPzZZk> MXKwMlAy6oDVMUFihKnPxE1? MVG3NkBp NXLiOIt7cW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?= NIHoV2kzOTB2OEe4OS=>
Mel-Juso  NVLT[|N4TnWwY4Tpc44hSXO|YYm= MnfSNE4xODIkgKOx5qCK|ryP NV7sVYF5OjRiaB?= Mn3Td5VxeHKnc4Pld{BxcG:|cHjvdplt[XSrb36gc4YheGixc4DoZZRq\HmuIHnuc5NqfG:uIEOtb4lv[XOnIHTve45{fHKnYX2geIFz\2W2cx?= MViyNVA1QDd6NR?=
518A2 M2fZOGZ2dmO2aX;uJGF{e2G7 NWrzOIo2OC5yMEJihLMy6oDLzszN NIDlR3czPCCq NGLKN3h{fXCycnXzd4V{KHCqb4PwbI9zgWyjdHnvckBw\iCyaH;zdIhifGmmeXygbY5we2m2b3ygN{1scW6jc3Wg[I94dnO2cnXhcUB1[XKpZYTz MlruNlExPDh5OEW=
PC3  NHGzVlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH3y[lEzPGh? NGnuSXdIUTVywrC9JFExOCCwTR?= MmTDNlA2PTFyNkG=
U87MG MnXvSpVv[3Srb36gRZN{[Xl? NFPrdWQxNjFvMTFOwG0> NEP2NmczPOLCiXlCpC=> MmP3SG1UVw>? NW\6Nnl3cW6qaXLpeJMhWEl|Sz3t[YRq[XSnZDDzbYdv[Wyrbne= MY[xPVY{OzZ6Mx?=
U138MG MYjGeY5kfGmxbjDBd5NigQ>? NF\ROYMxNjFvMTFOwG0> NYHkdGVMOjUkgJnoxsA> MWTEUXNQ Ml;pbY5pcWKrdIOgVGk{Uy2vZXTpZZRm\CC|aXfuZYxqdmd? NXfKb4EzOTl4M{O2PFM>
U118MG NFXROW9HfW6ldHnvckBCe3OjeR?= NH3SXHkxNjFvMTFOwG0> NF[3N48zPOLCiXlCpC=> MVvEUXNQ NHzaXGRqdmirYnn0d{BRUTONLX3l[IlifGWmIIPp[45idGmwZx?= NImxXXoyQTZ|M{[4Ny=>
U87MG NXHSZo5NT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml7kTWM2OD1yLkG0JO69VQ>? NYjvSJQzOTl3OESyNlc>
IGROV-1 M4jId2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVPXPXRmUUN3ME2wMlA3KM7:TR?= NGHnRYkyQTV6NEKyOy=>
DETROIT562 MknJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTBwMUOg{txO NWHaNI1wOTl3OESyNlc>
PC3  MnfKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHPrWIpKSzVyPUCuNVAh|ryP MmXHNVk2QDR{Mke=
SKOV-3 MoD2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTBwMUKg{txO NVHFT5N[OTl3OESyNlc>
HUVEC NVrrU5JlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFPIc3FKSzVyPUCuNFgh|ryP M4m5flE6PTh2MkK3
UCH-1  NW\2eZFQTnWwY4Tpc44hSXO|YYm= MUSwMVUh|ryP M3TYbIlvcGmkaYTzJJRp\SCyaH;zdIhwenmuYYTpc44hd2ZiYn;0bEBCU1RiYX7kJI1VV1JiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MXexPVUzQDR2MR?=
UCH-1  NF\VS4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDqRYMxOC5yMT2xNEDPxE1? NWfvVld3PiCm M16zPYlvcGmkaYTzJJBzd2yrZnXyZZRqd25iZH;z[UBl\XCnbnTlcpRtgQ>? MmezNVk2Ojh2NEG=
UCH-1  NG\KZXNCeG:ydH;zbZMhSXO|YYm= NGXzcIsxNjFvMUCg{txO NVjxSndIOjRiaB?= MkLLSG1UVw>? M1TWV4lv\HWlZYOgZZBweHSxc3nz MlW1NVk2Ojh2NEG=

多くの細胞株試験データを見る場合、クリックしてください

体内試験 When tumors reach 50-100 mm3, animals are randomized and treated with vehicle or PI-103. PI-103 exhibits significant activity, decreasing average tumor size by 4-fold after 18 days. [2] Mice treated with PI-103 have no obvious signs of toxicity premorbidly (based on body weight, food and water intake, activity, and general exam) or at necropsy. Treated tumors display decreased levels of phosphorylated Akt and S6, consistent with blockade of p110α and mTOR. PI-103 treatment is cytostatic to glioma xenografts. [2]

お薦めの試験操作(参考用のみ)

キナーゼ試験:[3]
+ 展開

Enzyme Assays:

Phosphatidylinositide 3-kinase inhibitory activity was determined using a scintillation proximity assay in the presence of 1 μmol/L ATP. Inhibition of mTOR protein kinase was determined using a TR-FRET-based LanthaScreen method from Invitrogen. Compounds were assayed at a maximum concentration of 10 μmol/L in the presence of 1 μmol/L ATP, and IC50 values were determined using GraphPad Prism software.
細胞試験: [2]
+ 展開
  • 細胞株: U87MG cells
  • 濃度: 0.5 μM
  • 反応時間: 24 hours
  • 実験の流れ: U87MG cells are treated with PI-103 for 24 hours. Cell death is quantified by colorimetric determination of LDH activity using a cytotoxicity detection kit. Percentage of cell death (mean of three 12-well plates per experimental point) is calculated [(experimental value- low control)/(high control -low control) × 100], where the low-control cells are DMSO treated and high-control cells are Triton treated (1% Triton X-100, 30 min, 37 °
    (参考用のみ)
動物試験:[2]
+ 展開
  • 動物モデル: 6- to 12-week-old Balbc nu/nu mice bearing U87MG:ΔEGFR cells
  • 製剤: 50% DMSO
  • 投薬量: 5 mg/kg
  • 投与方法: Administered via i.p.
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 24 mg/mL (68.89 mM)
Water Insoluble
Ethanol Insoluble
体内 順序で溶剤を入れること:
1% DMSO+30% polyethylene glycol+1% Tween 80
30 mg/mL

* 溶解度検測はSelleck技術部門によって行いますので、文献より提供された溶解度と差異がある可能性がありますが、生産工芸と不同ロット(lot)で起きる正常な現象ですから、ご安心ください。

化学情報

分子量 348.36
化学式

C19H16N4O3

CAS No. 371935-74-9
保管
別名 N/A

便利ツール

モル濃度計算器

モル濃度計算器

解決のために必要とされるマス、ボリュームまたは濃度を計算してください。

マス (g) = 濃度 (mol/L) x ボリューム (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • マス
    濃度
    ボリューム
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備することを要求される希釈剤を計算してください. セレック希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 輸入 輸出 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

マス 濃度 ボリューム 分子量

技術サポート

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

Handling Instructions

他の質問がある場合は、お気軽くお問合せください。

  • * 必須

Related Antibodies

PI3K信号経路図

PI3K Inhibitors with Unique Features

相関PI3K製品

Tags: PI-103を買う | PI-103 ic50 | PI-103供給者 | PI-103を購入する | PI-103費用 | PI-103生産者 | オーダーPI-103 | PI-103化学構造 | PI-103分子量 | PI-103代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID